Quanterix
Quanterix Counting on Multi-Marker Approach as Differentiator in Crowded Alzheimer's Dx Field
Premium
The company expects its five-marker LucentAD Complete test to offer higher performance than single-marker assay and to secure higher reimbursement.
The field's rapid advances make securing reimbursement an important area of focus, researchers in a recent commentary argued.
UltraDx Bio Receives Chinese Clinical Registration Approval for UD-X Immunoassay Analyzer
With the approval, the UD-X analyzer, which uses Quanterix's single-molecule array technology, can be used for clinical applications in China.
Quanterix Q2 Revenues Rise 11 Percent
The company reported revenue of $34.4 million, up from $31.0 million in Q2 2023 and beating the consensus Wall Street estimate of $33.7 million.
Davos Alzheimer's Collaborative Creates Initiative to Improve Alzheimer's Diagnosis
Under the program, blood biomarkers and confirmatory diagnostic testing will be used to increase diagnosis of Alzheimer’s disease and related dementias.
May 30, 2024
May 7, 2024
Quanterix Q1 Revenues up 13 Percent
Apr 16, 2024
Feb 29, 2024
Quanterix Q4 Revenues up 22 Percent
Feb 8, 2024
Aug 8, 2023
Quanterix Q2 Revenues Rise 32 Percent
Apr 20, 2023
Mar 6, 2023